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We thank Dr McKay for her comments
regarding our article. We examined the
relative safety in off-pump coronary
artery bypass grafting (CABG) of
two volume replacement fluids in
widespread use at the time we con-
ducted our study.1 Dr McKay argues
that the questions we investigated are
moot, that the fluids whose safety we
investigated are not in widespread
contemporary use, and that there
were methodologic flaws in our study
conduct. We will now address each
of Dr McKay’s arguments, showing
that the choice between the volume re-
placement fluids we studied remains
clinically relevant, that her methodo-
logic concerns are overstated, and
that our findings raise a series of
further questions.
Dr McKay states that there is exist-
ing evidence demonstrating that use of
high molecular weight (HMW) hetas-
tarch, one of the fluids we studied, is
associated in both cardiac and noncar-
diac surgery with greater blood loss
than is either low molecular weight
(LMW) hetastarch or albumin. Dr
McKay offers two examples of prior
studies of bleeding risk in cardiac sur-
gery. Unfortunately, whereas we ex-
amined bleeding risk in off-pump
CABG, the first of the cardiac papers
Dr. McKay cites2 investigated the im-
pact of hetastarch and albumin as
pump prime in on-pump cardiac pro-
cedures, and the second3 examined
the impact of hydroxyethyl starch
(Voluven), an LMW hetastarch, in or-
thopedic procedures. Generalization
of findings from either of these studies
to the risk posed by HMW hetastarch
in off-pump procedures is at best prob-
lematic. The differences between the
hemodynamic properties of on-pump
versus off-pump cardiac procedures
are well documented.4-7 McKay also
cites two prior reviews of the risks as-
sociated with volume replacement
fluids in noncardiac surgery. The first8
cites 10 studies of volume replacement
that actually examined the effects of its
use in cardiac surgery. All of theseardiovascular Surgery c March 2010studies of cardiac surgery examined
on-pump procedures and/or other use
of fluids and/or postoperative fluid
administration. None of these studies
examined perioperative administration
of hetastarch versus albumin in off-
pump procedures. The second cited ar-
ticle9 again examined only on-pump
cardiac procedures. Perhaps Dr McKay
inadvertently switched the citations to
Gandhi3 and Wilkes9 and their associ-
ates. That second article9 was actually
one of the sparks for our decision to in-
vestigate risks associated with volume
replacement fluid use in off-pump pro-
cedures. Parenthetically, that second ar-
ticle is considered by many to have
established that the particular formula-
tion of hetastarch carries too high
a bleeding risk for it to be used routinely
for volume replacement in CABG pro-
cedures performed on-pump. We in-
stead examined the bleeding risk
carried by HMW hetastarch in off-
pump procedures. Approximately
20% of the CABG procedures in
2007 were performed off-pump.10 We
note that the recently published results
of a large-scale randomized clinical trial
that favor on-pump over off-pump pro-
cedures may impact this practice pat-
tern, contributing to an increase in the
relative frequency of on-pump proce-
dures.11
Second, Dr McKay was not clear re-
garding the hetastarch formulation
used in our study. Our study examined
Hextend, a formulation of HMW hy-
droxyethyl starch 6% in a buffered
electrolyte dextrose solution. This
composition of the test solution in-
fused is identified on our article’s first
page, and its administration is dis-
cussed in the section describing ran-
domization and sample size. We
inadvertently omitted mentioning this
fluid a second time in the Clinical Pro-
tocol section of our article. We apolo-
gize for any confusion this may have
caused for Dr McKay or other readers.
Participants were randomly assigned
to receive an initial infusion of 1000
mL of Hextend or 1000 mL of albu-
min. Any subsequent infusions of
Letters to the Editorcolloid used only albumin. These sub-
sequent infusions were provided at the
discretion of the attending physicians.
Dr McKay next asks about blinding
and transfusion practices. This portion
of the protocol is presented in the arti-
cle’s section on Power Analysis. Inten-
sivists providing postoperative care
were blinded to the fluids infused,
but the anesthesiologists infusing the
fluids were not blinded. We followed
this protocol for several reasons. Cur-
rent requirements in this era of regula-
tory compliance call for transparent
intravenous tubing. Given that albu-
min and hetastarch fluids have differ-
ent appearances, it would have been
difficult to assure a blinded process
in the clinical setting of the operating
room even if we had somehow cov-
ered the 500-mL containers from
which the fluid was being infused. Dr
McKay also complains that we do
not present standardized (protocol or
goal-driven) fluid administration. Pre-
suming that Dr McKay is referring to
fluid administered after the first liter
(administered per protocol and de-
scribed in our article’s Statistical
Power Analysis section), we state later
in that section that the remaining stan-
dard operative regimen of crystalloids
and blood products in the periopera-
tive period were administered at the
discretion of the anesthesiologist. We
note in the following paragraphs on
Clinical Protocol that postoperative
fluid management was at the discretion
of the attending intensivist according
to each patient’s clinical status. The
fluid management policy in both pe-
riods was selected so that our study
could examine the impact of the initial
fluid used for volume replacement on
vascular outcome in patients receiving
the careful care provided following the
protocols otherwise used to guide care
in nonresearch environments.
Dr McKay also questions what fac-
tors (beyond infusion of the randomly
assigned fluid) explain the increased
blood loss and transfusion requirement
in members of the hetastarch branch.
She proposes that the 287.2-mLThe Journalgreater infusion of colloid in the initial
preoperative preparation explains the
165.0-mL greater postoperative chest
tube drainage and the 0.73-unit greater
transfusion of packed red blood cells.
The hypothesized mechanism for this
effect is the greater volume of colloid
causing expanded plasma volume,
increased clotting factor dilution, de-
creased blood viscosity, and increased
venous return and cardiac output.
These mechanisms might be believ-
able if the 287.2-mL increase was
from a baseline of 0 mL. Instead, it
represents a 24.1% increase from the
1192.3 mL of colloid administered to
those in the albumin arm (see Table
1). Combining colloid with crystalloid
and cell salvage, those in the hetas-
tarch arm were infused with 4944.9
mL while those in the albumin arm
were infused with 4693.7 mL, a differ-
ence of 251.4 mL or 5.4% of the vol-
ume of fluids administered in the
perioperative period. We do not think
this 5.4% difference in fluid adminis-
tered is clinically significant. We also
note that albumin was the only fluid
administered after the first liter.
We agree with Dr McKay that the
question of which fluids should be con-
sidered optimal for volume replace-
ment in CABG procedures is not
settled. We are now actively involved
in designing further studies using asso-
ciations with the outcomes examined
in our study and other outcomes to ex-
amine the effectiveness and risks of us-
ing albumin versus other fluids in this
clinical context. We trust that these
and other studies will provide a meth-
odologically sound evidence base that
can be used to guide future clinical de-
cision-making in this area.
Howard Barkan, DrPH
University of California
Berkeley, Calif
References
1. Hecht-Dolnik M, Barkan H, Taharka A, Loftus J.
Hetastarch increases the risk of bleeding complica-
tions after off-pump coronary bypass surgery:
a randomized clinical trial. J Thorac Cardiovasc
Surg. 2009;138:703-11.
2. Kuitunen A, Hynynen M, Salmenpera¨ M,
Heinonen J, Vahtera E, Verkkala K, et al. Hydrox-of Thoracic and Cardiovascular Surgeyethyl starch as a prime for cardiopulmonary bypass:
effects of two different solutions on haemostasis.
Acta Anaesthesiol Scand. 1993;37:652-8.
3. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R,
Miller D, Shangraw RE, et al. Volume replacement
therapy during major orthopedic surgery using
Voluven (hydroxyethyl starch 130/0.4) or hetastarch.
Anesthesiology. 2007;106:1120-7.
4. Warren BB, Durieux ME. Hydroxyethyl starch:
safe or not? Anesth Analg. 1997;4:206-12.
5. Lo B, Fijnheer R, Castigliego D, Borst C,
Kalkman CJ, Nierich AP. Activation of hemostasis
after coronary artery bypass grafting with or
without cardiopulmonary bypass. Anesth Analg.
2004;99:634-40.
6. Ascione R, Williams S, Lloyd CT, Sundaramoorthi T,
Pitsis AA, Angelini GD. Reduced postoperative
blood loss and transfusion requirement after
beating-heart coronary operations: a prospective
randomized study. J Thorac Cardiovasc Surg.
2001;121:689-96.
7. Reston JT, Tregear SJ, Turkelson CM. Meta-
analysis of short-term and mid-term outcomes
following off-pump coronary artery bypass
grafting. Ann Thorac Surg. 2003;76:1510-5.
8. Barron ME, Wilkes MM, Navickis RJ. A system-
atic review of the comparative safety of colloids.
Arch Surg. 2004;139:552-63.
9. Wilkes MM, Navickis RJ, Sibbald WJ. Albumin
versus hydroxyethyl starch in cardiopulmonary
bypass surgery: a meta-analysis of postoperative
bleeding. Ann Thorac Surg. 2001;72:527-33.
10. National Society of Thoracic Surgeons Adult Car-
diac Database: Spring Report; 2007 www.stsa.org/
sections/stsnationaldatabase/publications/executive/
article.html.
11. Shroyer AL, Grover FL, Hattler B, et al. On-pump
vs off-pump coronary-artery bypass surgery. New
Engl J Med. 2009;361:1827-37.
doi:10.1016/j.jtcvs.2009.10.017REGIONALWALL MOTION
ABNORMALITIES AND
SCARRING IN SEVERE
FUNCTIONAL ISCHEMIC
MITRAL REGURGITATION:
A PILOT CARDIOVASCULAR
MAGNETIC RESONANCE
IMAGING STUDY
To the Editor:
We read with interest Flynn and col-
leagues’ article1 concerning preopera-
tive evaluation with cardiac magnetic
resonance imaging (MRI) in patients
undergoing coronary artery bypass
grafting and mitral valve annuloplasty
for ischemic mitral valve regurgitation
(IMVR).
In our experience, cardiac MRI has
been advocated for preoperative rou-
tine evaluation of patients withry c Volume 139, Number 3 795
